A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.
A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.
复制标题
DOI：
10.1371/journal.pone.0048993
复制
发表时间：
2012
期刊：
影响因子：
3.7
通讯作者：
Radvanyi F
中科院分区：
文献类型：
--
作者：
Neuzillet Y;Paoletti X;Ouerhani S;Mongiat-Artus P;Soliman H;de The H;Sibony M;Denoux Y;Molinie V;Herault A;Lepage ML;Maille P;Renou A;Vordos D;Abbou CC;Bakkar A;Asselain B;Kourda N;El Gaaied A;Leroy K;Laplanche A;Benhamou S;Lebret T;Allory Y;Radvanyi F
TP 53和FGFR 3突变是膀胱癌中最常见的突变。FGFR 3突变在低级别低阶段肿瘤中最常见，而TP 53突变在高级别高阶段肿瘤中最常见。一些研究报告FGFR 3和TP 53突变是相互排斥的事件，而其他研究报告它们是独立的。我们对膀胱癌中FGFR 3和TP 53突变的已发表结果（535个肿瘤，6篇出版物）和382个肿瘤的其他未发表数据进行了荟萃分析。TP 53和FGFR 3突变对于所有肿瘤（OR = 0.25 [0.18-0.37]，p = 0.0001）或单独pT 1肿瘤（OR = 0.47 [0.28-0.79]，p = 0.0009）而言不是独立事件。 然而，如果分析仅限于pTa肿瘤或肌肉浸润性肿瘤，则FGFR 3和TP 53突变是独立事件（分别为OR= 0.56 [0.23-1.36]（p = 0.12）和OR = 0.99 [0.37-2.7]（p =0.35））。 在按阶段和等级对肿瘤进行分层后，在所考虑的五个肿瘤组（pTaG 1和pTaG 2一起、pTaG 3、pT 1G 2、pT 1G 3、pT 2 -4）中未检测到依赖性。这些发现的差异可以归因于膀胱癌中存在两种不同的肿瘤进展途径：CIS途径，其中FGFR 3突变罕见，以及Ta途径，其中FGFR 3突变频繁。TP 53突变发生在CIS途径的最早阶段，而它们发生在Ta途径的更晚阶段，在T1 G3或肌肉侵入阶段。
TP53 and FGFR3 mutations are the most common mutations in bladder cancers. FGFR3 mutations are most frequent in low-grade low-stage tumours, whereas TP53 mutations are most frequent in high-grade high-stage tumours. Several studies have reported FGFR3 and TP53 mutations to be mutually exclusive events, whereas others have reported them to be independent. We carried out a meta-analysis of published findings for FGFR3 and TP53 mutations in bladder cancer (535 tumours, 6 publications) and additional unpublished data for 382 tumours. TP53 and FGFR3 mutations were not independent events for all tumours considered together (OR = 0.25 [0.18–0.37], p = 0.0001) or for pT1 tumours alone (OR = 0.47 [0.28–0.79], p = 0.0009). However, if the analysis was restricted to pTa tumours or to muscle-invasive tumours alone, FGFR3 and TP53 mutations were independent events (OR = 0.56 [0.23–1.36] (p = 0.12) and OR = 0.99 [0.37–2.7] (p = 0.35), respectively). After stratification of the tumours by stage and grade, no dependence was detected in the five tumour groups considered (pTaG1 and pTaG2 together, pTaG3, pT1G2, pT1G3, pT2-4). These differences in findings can be attributed to the putative existence of two different pathways of tumour progression in bladder cancer: the CIS pathway, in which FGFR3 mutations are rare, and the Ta pathway, in which FGFR3 mutations are frequent. TP53 mutations occur at the earliest stage of the CIS pathway, whereas they occur would much later in the Ta pathway, at the T1G3 or muscle-invasive stage.
登录
查看更多内容
影响因子：
3.4
作者：
Knowles MA
通讯作者：
Knowles MA
影响因子：
9.3
作者：
Bakkar, AA;Quach, V;Grandchamp, B
通讯作者：
Grandchamp, B
影响因子：
8
作者：
Eymin, B;Leduc, C;Gazzeri, S
通讯作者：
Gazzeri, S
影响因子：
7.2
作者：
Liberati, Alessandro;Altman, Douglas G;Moher, David
通讯作者：
Moher, David
影响因子：
11.5
作者：
Hernández, S;López-Knowles, E;Real, FX
通讯作者：
Real, FX